 |
|
|
| |
USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 INFECTION IN PATIENTS COINFECTED WITH HIV (Interim results)
|
| |
| |
Reported by Jules Levin
EASL 2014 April 10-13 London, UK
Anu Osinusi1,2, Kerry Townsend1, Amy Nelson1, Anita Kohli3,4, Eric Meissner1, Chloe Gross3, Michael A. Polis1, Phil S Pang5, William T. Symonds5, Mohammed M. Sajadi1, John Hogan6, G. Mani Subramanian5, John G. McHutchison5, Henry Masur4, Shyam Kottilil1 for the NIAID/CC Hepatitis C ERADICATE team1,3,4
1Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, 2Dept of Infectious Diseases, University of Maryland, Baltimore, 3Leidos /SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, Maryland , 4Critical Care Medicine Department, NIH, Bethesda, Maryland , 5Gilead Sciences, Foster City, California, 6Unity Health Care Inc, Washington DC
|
| |
|
|
|
|
|
